SEOM clinical guideline for the management of malignant melanoma (2017)

All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrocal, A., Arance, A., Castellon, V. E., de la Cruz, L., Espinosa, E., Cao, M. G., Larriba, J. L. G., Márquez-Rodas, I., Soria, A., Algarra, S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Clinical Guides in Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785602/
https://www.ncbi.nlm.nih.gov/pubmed/29116432
http://dx.doi.org/10.1007/s12094-017-1768-1
Descripción
Sumario:All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.

Ejemplares similares